• Ganetespib (STA-9090): Precision Hsp90 Inhibition in Cancer

  2026-08-03

  Ganetespib (STA-9090) redefines Hsp90 inhibition for cancer research, offering nanomolar potency and workflow flexibility across tumor models. Discover how applied protocols, troubleshooting insights, and mechanistic context unlock the full potential of this triazolone small molecule inhibitor from APExBIO.

• BET Bromodomain Inhibitor (+)-JQ1: Mechanistic Depth and Eme

  2026-08-03

  Explore the advanced mechanisms and practical research applications of Bromodomain Inhibitor, (+)-JQ1. This cornerstone article provides new scientific insights into BET bromodomain inhibitor function, with a unique focus on assay design and translational potential.

• 3-Bromopyruvate and Cetuximab Synergy Overcomes CRC Resistan

  2026-08-02

  This study demonstrates that 3-bromopyruvate, combined with cetuximab, reverses cetuximab resistance in colorectal cancer through coordinated induction of autophagy-dependent ferroptosis and apoptosis. The findings highlight a mechanistically distinct, multi-pathway strategy for targeting refractory metastatic colorectal cancer.

• Belinostat (PXD101): Optimizing HDAC Inhibition in Cancer Mo

  2026-08-01

  Belinostat (PXD101) sets a benchmark in pan-HDAC inhibition, enabling precise epigenetic modulation for preclinical cancer research. This guide translates the latest reference insights into actionable protocols, troubleshooting, and advanced strategies for robust results in bladder and prostate cancer models.

• Redefining Senescent Cell Detection for Translational Succes

  2026-07-31

  A deep dive into the mechanistic role of SA-β-Gal as a senescence biomarker, the evolving standards for translational senescent cell assays, and strategic guidance for deploying advanced staining technologies—anchored by insights from the APExBIO Cell Senescence β-Galactosidase Staining Kit (K2185). This article bridges bench and bedside by escalating discussion beyond technical protocols, synthesizing competitive landscape analysis, clinical implications, and actionable recommendations for drug screening and aging research.

• EPI-001: Androgen Receptor N-Terminal Domain Inhibitor Workf

  2026-07-31

  EPI-001, a first-in-class androgen receptor N-terminal domain inhibitor, uniquely enables researchers to target both full-length and splice variant AR signaling in prostate and triple-negative breast cancer models. Its robust effect on metastasis and EMT pathways, as highlighted in recent mechanistic studies, positions it as a transformative tool for translational oncology research.

• Ceftolozane-tazobactam: Advances in Nosocomial Pneumonia The

  2026-07-30

  This article analyzes the innovation and clinical relevance of ceftolozane-tazobactam for nosocomial pneumonia, focusing on its potent activity against multidrug-resistant Pseudomonas aeruginosa. The reference study’s structural, pharmacodynamic, and resistance data highlight its value for both translational research and clinical assay development.

• LLY-507: SMYD2 Inhibitor Workflows for Cancer and Fibrosis R

  2026-07-30

  LLY-507 from APExBIO stands out as a potent, selective SMYD2 inhibitor, enabling researchers to dissect epigenetic mechanisms in cancer and fibrosis with high precision. This guide translates recent breakthroughs into actionable protocols and troubleshooting insights for advanced cellular and disease modeling applications.

• LG 101506 (RXR Modulator): Advanced Tools for RXR Signaling

  2026-07-29

  LG 101506 (RXR modulator) from APExBIO empowers researchers to dissect RXR signaling pathways and their roles in cancer immunology and metabolism. This article translates new mechanistic insights and recent findings into actionable workflows, troubleshooting strategies, and protocol enhancements for RXR-driven experimental systems.

• SGI-1027: Optimizing DNA Methyltransferase Inhibition in Can

  2026-07-29

  SGI-1027 stands out as a robust DNA methyltransferase inhibitor, uniquely enabling targeted CpG demethylation and tumor suppressor gene reactivation. This guide delivers applied workflows, troubleshooting strategies, and actionable protocol parameters to maximize impact in epigenetic cancer research.

• HBsAg Hijacks TBK1 to Suppress Interferon and Induce Autopha

  2026-07-28

  A recent study elucidates how hepatitis B surface antigen (HBsAg) directly interacts with TANK-binding kinase 1 (TBK1) to suppress type I interferon production and induce early autophagy. This mechanism reveals a pivotal viral strategy for immune evasion and persistent infection, with implications for antiviral target development.

• Z-IETD-FMK: Caspase-8 Inhibition for Apoptosis & Immune Rese

  2026-07-28

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) is a highly specific, irreversible inhibitor of caspase-8. It is widely used to dissect apoptotic and immune cell signaling pathways, particularly in models of T cell activation and TRAIL-mediated apoptosis. APExBIO offers this compound for research use, supporting reliable modulation of cell death mechanisms.

• Tomivosertib: Precision MNK1 Inhibitor Workflows & Troublesh

  2026-07-27

  Tomivosertib empowers researchers to dissect translational regulation by selectively inhibiting MNK1/2 in cancer, metabolic, and neuronal models. This article presents advanced experimental workflows, key innovations from structure-guided design, and troubleshooting strategies—enabling rigorous interrogation of the MNK-eIF4E signaling axis.

• Disrupting c-MYC-G9a-FTH1 Axis in Breast Cancer via BRD4 and

  2026-07-27

  This study demonstrates that co-targeting BET bromodomain BRD4 and RAC1 signaling disrupts the c-MYC-G9a-FTH1 axis and downregulates HDAC1, leading to suppressed growth and stemness in multiple breast cancer subtypes. The findings reveal a context-dependent epigenetic vulnerability with implications for refined cancer therapy and mechanistic research.

• Super-Enhancer Hijacking of LINC01977 Fuels Early LUAD Progr

  2026-07-26

  Zhang et al. identified that super-enhancer-driven upregulation of the lncRNA LINC01977 promotes malignancy in early-stage lung adenocarcinoma (LUAD) by intensifying canonical TGF-β/SMAD3 signaling. These findings clarify a novel epigenetic mechanism linking tumor microenvironment cues to aggressive LUAD phenotypes and highlight potential epigenetic intervention targets.

11609 records 1/774 page Next 12345 下5页 Last page